NCT05988216招募中不适用
A Clinical Study on the Safety and Efficacy of BRL-301 (Allogeneic Chimeric Antigen Receptor T Cell Injection Targeting CD19 Gene) in the Treatment of Refractory Systemic Lupus Erythematosus
Bioray Laboratories1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2023年8月14日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- The safety of BRL-301 in refractory systemic lupus erythematosus
研究概览
简要总结
This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the refractory systemic lupus erythematosus.
详细描述
The study had the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment and Follow-up.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age range from 18 to 65 years old (including threshold), regardless of gender;
- •Subjects diagnosed with SLE according to the 2019 EULAR/ACR SLE classification criteria; ANA ≥ 1:80, or positive for anti dsDNA and/or anti Sm antibodies;
- •The condition becomes active again after conventional treatment is ineffective or the disease relapses. Conventional treatment is defined as the use of two or more drugs, including corticosteroids (more than 1mg/kg/d) and any one or more of the following immunomodulatory drugs for over six months: antimalarial drugs, cyclophosphamide, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, as well as biologics including rituximab, belimumab, etanercept, etc.
- •At least one BILAG2004 Class A or two Class B score, or both;
- •SELENA-SLEDAI score ≥ 8 points;
- •The positive expression and expression rate of CD19 on peripheral blood B cells determined by flow cytometry;
- •The functions of important organs meet the following requirements:
- •Bone marrow function needs to meet:
- •White blood cell count ≥ 3 × 109/L;
- •Neutrophil count ≥ 1 × 109/L (no Colony-stimulating factor treatment within 2 weeks before examination);
- •Platelets ≥ 50 × 109/L;d. Hemoglobin ≥ 80g/L
- •Liver function:
- •Alanine Aminotransferase (ALT) ≤ 3 × ULN;
- •Asparagus cochinchinensis transase (AST) ≤ 3 × ULN;
- •Total Bilirubin (TBIL) in serum ≤ 1.5 × ULN (excluding Gilbert syndrome, total bilirubin ≤ 3.0 × ULN); Renal function: Creatinine Clearance Rate (CrCl) ≥ 60 ml/minute (Cockcroft/Fault formula) ;
- •Coagulation function:
- •International Normalized Ratio (INR) ≤ 1.5 × ULN,
- •Prothrombin time (PT) ≤ 1.5 × ULN.
- •Cardiac function: good hemodynamic stability, left ventricular Ejection fraction (LVEF) ≥ 55%;
- •Female patients of childbearing potential and male patients whose female sexual partners are of childbearing age should adopt medically recognized contraceptive measures or abstain from sex within at least 6 months after infusion of BRL-301; female patients of childbearing age should have a negative serum HCG test result within 7 days before study enrollment and be not breastfeeding;
- •Willing to participate in this clinical study, sign an ICF, and complete follow-ups, with good compliance.
排除标准
- •Have a serious history of Drug allergy or allergic constitution;
- •Fungi, bacteria, viruses, or other infections that are uncontrollable or require intravenous medication treatment exist or are suspected;
- •Central nervous system disease caused by SLE or not (including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident, encephalitis, central nervous system Vasculitis);
- •Individuals with relatively serious heart diseases, such as angina pectoris, myocardial infarction, heart failure, and arrhythmia;
- •Subjects with congenital immunoglobulin deficiency;
- •Other malignant tumors (excluding non Melanoma skin cancer, cervical cancer in situ, bladder cancer cancer and breast cancer that have survived for more than 5 years without disease);
- •Subjects with end-stage renal failure;
- •Have received any of the following SLE treatments:
- •Corticosteroid (defined as prednisone or equivalent>20 mg/day) of therapeutic dose were used before enrollment or within 72 hours before BRL-301 infusion.
- •Use any other clinical study drugs for SLE within 4 weeks prior to enrollment. However, if the research treatment period is ineffective or the disease progresses, and at least 3 half-lives have passed before enrollment, enrollment is allowed.
- •Had received anti CD20 monoclonal antibody (such as Rituximab) within 4 weeks before screening, tetaximab within 6 weeks, or belizumab within 12 weeks.
- •Previous CAR-T cell or other genetically modified T Cell therapy.
- •Subjects with positive hepatitis B B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and HBV DNA titer in peripheral blood higher than the upper limit of detection; Patients with positive hepatitis C virus (HCV) antibodies and positive peripheral blood HCV RNA; People who are positive for human immunodeficiency virus (HIV) antibodies; Those who have tested positive for syphilis;
- •Having mental illness and severe cognitive impairment;
- •Those who have participated in other clinical trials within the first 3 months of enrollment;
- •Pregnant or intending to conceive women;
- •Patients who are unsuitable for being included into this study as deemed by the investigator due to other reasons.
研究组 & 干预措施
BRL-301
Experimental
Allogeneic CD19-targeted Chimeric AntigenReceptor (CAR) T Cells
干预措施: BRL-301 (Biological)
结局指标
主要结局
The safety of BRL-301 in refractory systemic lupus erythematosus
时间窗: 3 months
Incidence and severity of AEs and SAEs, including changes in laboratory values, ECG and vital signs as assessed by CTCAE v5.0.
次要结局
- The efficiency of BRL-301 in refractory systemic lupus erythematosus(3 months)
- Cellular kinetics(3 months)
研究者
研究点 (1)
Loading locations...
相似试验
Enrolling By Invitation
不适用
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune DiseasesSystemic Lupus Erythematosus (SLE)Inflammatory MyopathyANCA Associated Systemic VasculitisSystemic SclerosisAntiphospholipid SyndromeSjogren's SyndromeNCT05859997Bioray Laboratories15
已完成
1 期
Safety and Bioavailability of IV and SC LBR-101Bioavailability and PharmacokineticsNCT01991509Teva Branded Pharmaceutical Products R&D, Inc.36
Unknown
2 期
Oral BBR-012 in the Treatment of Diabetic Foot Ulcers, Proof of Concept StudyDiabetic Foot UlcerNCT01342497Bridge BioResearch Ltd.60
尚未招募
1 期
Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.Triple Negative Breast CancerNCT02802423BioLite, Inc.44
招募中
1 期
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological MalignanciesGynecological Malignant TumorSolid TumorNCT05803018Sichuan Baili Pharmaceutical Co., Ltd.38